Updates are available Correction dated 2024-05-30
Click to view Correction: https://doi.org/10.1007/s10928-024-09923-w
-
Authors
Nasser, Azmi https://orcid.org/0000-0003-0514-8410
Gomeni, Roberto
Ceresoli-Borroni, Gianpiera
Xie, Lanyi
Busse, Gregory D.
Melyan, Zare
Rubin, Jonathan
- License Information
-
More Information
Article History
Received: 12 August 2022
Accepted: 10 March 2024
First Online: 5 April 2024
Change Date: 30 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10928-024-09923-w
Declarations
:
: Ethics approval was not required, as the study was conducted using computer simulations.
: GC, LX, GDB, ZM, and JR are employees of Supernus Pharmaceuticals, Inc.AN was an employee of Supernus Pharmaceuticals, Inc. at the time the study was conducted.RG was a paid consultant to Ironshore Pharmaceuticals, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Teva, Biomedical Science Institutes, Nanomi BVs, Laboratorios Liconsa, Massachusetts General Hospital, UCB, Recordati Rare Diseases, Indivior, Tris Pharma, and F. Hoffmann-La Roche.
